Olaparib, as a 3rd line treatment, improves survival of a subset of prostate cancer patients with certain genetic changes .

Some prostate cancers are inherited. Some of these cancers have changes in a gene called BRCA.

Some prostate cancers which are not inherited can sometimes have these BRCA changes as well.

Data presented at ESMO ( European Society of Medical Oncology) shows that the prostate cancers with BRCA gene changes derive the most benefit from Olaparib. When administered as a third line treatment ( after failure hormone injection, novel hormonal tablets and chemotherapy) , Olaparib makes these patients live longer.

ESMO Daily Reporter. PROFOUND: OVERALL SURVIVAL DATA WITH OLAPARIB HERALD PRACTICE-CHANGING TREATMENT OF METASTATIC PROSTATE CANCER.

Disclaimer: Please note- This blog is NOT medical advice. This blog is purely for information only and do check the the sources where cited. Please consult your own doctor to discuss concerns and options relevant to you.

The views expressed in this blog represent the author’s views held at the time of drafting the blog and is likely to change overtime, particularly when new evidence comes to light. The blog is not necessarily endorsed by any organisation the author is associated with and views are not substitute for professional advice.